A summary of the Advisory Committee for Immunization Practices (ACIP) use of a benefit-risk assessment framework during the first year of COVID-19 vaccine administration in the United States
Megan Wallace(Centers for Disease Control and Prevention), Julia W. Gargano(Canadian Institutes of Health Research), Danielle Moulia(Centers for Disease Control and Prevention), Hannah G. Rosenblum(National Center for Immunization and Respiratory Diseases), Stephen C. Hadler(The Task Force for Global Health), Tom T. Shimabukuro(Centers for Disease Control and Prevention), Karen R. Broder(Centers for Disease Control and Prevention), Sara E. Oliver(Centers for Disease Control and Prevention), Fiona P. Havers(Centers for Disease Control and Prevention), Kathleen Dooling(Pfizer (United States)), Christopher A. Taylor(Centers for Disease Control and Prevention), Sarah Meyer(Prisma)
Cited by 21
Related Papers
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
|The Lancet|2019|1.3k
Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021
|JAMA|2022|670
Changes in Influenza and Other Respiratory Virus Activity During the COVID-19 Pandemic — United States, 2020–2021
|MMWR Morbidity and Mortality Weekly Report|2021|611
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
|MMWR Morbidity and Mortality Weekly Report|2021|602
Prevention and Control of Seasonal Influenza with Vaccines
|MMWR Recommendations and Reports|2016|601